Home>Topics>Companies>Biogen Idec

Biogen Idec

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. Ultimate Stock-Pickers: Top Holdings of Top-Performing Managers

    Headlines

    Tue, 16 Dec 2014

    Name Star Rating Moat Rating Current Price (USD) Price/ FVE Fair Value Uncertainty Market Cap (USD Mil) % Stock Holdings Biogen BIIB 3 Wide 344.49 1.01 Medium 81,866 7.7 Amgen AMGN 4 Wide 164.53 0.92 Low 123,985 5.2 Eli Lilly LLY 2 Wide 69

  2. UPDATE 1- Biogen plans late-stage Alzheimer's trial, shares rise

    Headlines

    Tue, 2 Dec 2014

    Dec 2 (Reuters) - Biogen Idec Inc 's research chief on Tuesday said the company is planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug cut brain plaque...

  3. Biogen plans late-stage trial for Alzheimer's treatment

    Headlines

    Tue, 2 Dec 2014

    Dec 2 (Reuters) - Biogen Idec Inc 's research chief on Tuesday said the company was planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug cut brain plaque...

  4. BRIEF- Biogen shares rise on favorable Alzheimer's data, plans for larger trial

    Headlines

    Tue, 2 Dec 2014

    Dec 2 (Reuters) - Biogen Idec Inc : * Research chief says company plans phase III trial of experimental Alzheimer's drug BIIB037, based on promising interim data from early-stage trial * Says interim analysis indicates drug cut amyloid levels, had statistically

  5. Finding a Margin of Safety in a Fully Valued Market

    Headlines

    Fri, 21 Nov 2014

    share prices and contributing to its low uncertainty rating. However, new competition for Advate from the likes of Biogen Idec BIIB and Novo Nordisk NVO over the next few years could begin to erode the firm's dominant position in the U.S. market

  6. UPDATE 4- Biogen's Tecfidera sales miss estimates; confirms first PML case

    Headlines

    Wed, 22 Oct 2014

    Oct 22 (Reuters) - Biogen Idec Inc said on Wednesday sales of its big-selling new multiple sclerosis drug Tecfidera fell short of Wall Street's lofty expectations, and the company confirmed a serious...

  7. Biogen profit surges, but Tecfidera sales shy of Street view

    Headlines

    Wed, 22 Oct 2014

    Oct 22 (Reuters) - Biogen Idec Inc on Wednesday reported much higher third-quarter profit and revenue, even as its big-selling new oral multiple sclerosis drug Tecfidera fell short of lofty Wall...

  8. Momenta Shifts Operations on Generic Copaxone Approval Delay

    Commentary

    Fri, 1 Aug 2014

    in Copaxone sales this quarter, which ultimately reduces the market opportunity for Momenta as new oral drugs, like Biogen Idec ’s Tecfidera, alter the competitive landscape of the multiple sclerosis market. Additionally, Teva has now shifted

  9. UPDATE 4- Biogen revenue trounces forecast as MS drug sales surge

    Headlines

    Wed, 23 Jul 2014

    July 23 (Reuters) - Biogen Idec Inc reported blowout quarterly results and raised its full-year forecast on Wednesday on surging sales of its new Tecfidera oral treatment for multiple sclerosis,...

  10. Biogen's Strong 2Q Has Long-Term Impact on Value of MS Franchise; Significantly Raising Our FV

    Commentary

    Wed, 23 Jul 2014

    Biogen Idec reported second-quarter results that were ..... That said, we believe that investors in Biogen at recent prices assume a strong hemophilia ..... competitors), and a high success rate for Biogen 's novel drug candidates (many of which

« Prev12345Next »
Content Partners